A trial identified five drug combinations for the treatment of "ultra-high-risk" bone marrow cancer

A major new trial shows that a combination of five existing drugs can prolong the anti-cancer time of a patient with a highly aggressive type of bone marrow cancer

A cocktail of five drugs, combined with stem cell transplantation, enables patients with ultra-high-risk multiple myeloma to live longer than patients receiving standard treatment

The "MUK 9 Best Solutions" trial used a highly innovative method to open the door to the first tailor-made treatment for people at high risk of myeloma.

This is also the latest study that proves the benefits of drugs that combine different mechanisms of action to fight cancer evolution and drug resistance

A research team from the Institute of Cancer Research, London and Clinical Trials.

Their findings were presented at the annual meeting of the American Society of Hematology on Sunday

The five drugs used in the combination—bortezomib, lenalidomide, dalatuzumab, dexamethasone, and cyclophosphamide chemotherapy—are separately licensed and used in the clinic

Certain genetic changes make multiple myeloma (a type of bone marrow cancer) more aggressive, less responsive to treatment, and may relapse more quickly

There is currently no targeted treatment for these high-risk patients, and the prognosis is still unsatisfactory

The optimal trial included 107 high-risk myeloma patients recruited between 2017 and 2019

Patients in the best trial are more likely to live longer than MyXI patients during and after treatment before seeing their disease progression and symptoms worsen

The new findings represent a major advancement for high-risk myeloma patients and emphasize the need for tailored treatments based on the genetic makeup of each patient’s cancer, which is currently not routinely performed

This research is an independent academic trial, but received funding from pharmaceutical companies, production drug testing, Jensen and Bristol-Myers Squibb, as well as support from the David Forbes-Nixon Foundation in the United Kingdom through myeloma and NIHR biomedicine The research center is owned by the Royal Marsden NHS Trust and owned

Optimal is the first "digital comparator" trial for the treatment of multiple myeloma

This digital comparator trial provides a new framework to quickly track comparative evidence and help scientists get answers faster for patients whose clinical needs are not met

Therefore, optimal is a successful proof-of-principle study that supports the use of digital comparison arm trials in clinical development

Research leader, Dr.
Martin Kaiser, head of the Myeloma Molecular Therapy Group at the London Cancer Institute, and consultant hematologist at the Royal Marsden NHS Foundation, said:

"We know that patients with multiple myeloma with'ultra-high risk' genetic characteristics have malignant tumors that are not effective against standard treatment
.
In this study, we have identified a new five-drug combination that can be used in these patients Suppress myeloma for a longer period of time
.
Our research shows the benefits of genetic testing in identifying high-risk groups among myeloma patients, because we now have a new and better treatment option
.

He said: "All these drugs have been personally approved and can be purchased, so we know they are safe, which means that patients may be able to get new combinations soon
.
I hope the NHS will consider our data as soon as possible
.
"

Professor Christian Hailin, Chief Executive Officer of the London Cancer Institute said:

"So far, patients with the highest-risk multiple myeloma have no customized treatment options, although we know they are likely to relapse under existing treatment options
.
This research represents an important step forward for these The patient provided more effective treatment
.

This exciting trial is also the first of its kind.
It uses sophisticated statistical analysis to compare the results with previous studies rather than with a control group
.
The new test method has great potential to deliver much-needed new therapies to the clinic faster, and it also reduces the cost of the test
.
"

Dr Sarah Brown, Director of Early Clinical Trials, Department of Clinical Trial Research, University of Leeds, said:

"We are really pleased to see the positive results of this trial and to be able to demonstrate how the application of new statistical methods can lead to effective trial design, guidance and dissemination
.
This research and the methods used indeed have the potential to have a broad impact on the research.

.
"